melatonin has been researched along with Diabetic Retinopathy in 25 studies
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent evidence suggests that diabetic retinopathy (DR) is associated with abnormal melatonin regulation, possibly related to dysfunction of the melanopsin-expressing intrinsically photosensitive retinal ganglion cells." | 8.02 | Sleep variability, 6-sulfatoxymelatonin, and diabetic retinopathy. ( Chailurkit, LO; Chirakalwasan, N; Gerber, BS; Nimitphong, H; Pinyopodjanard, S; Reutrakul, S; Saetung, S; Sirisreetreerux, S; Sujirakul, T, 2021) |
| " Melatonin is a strong anti-inflammatory hormone, mediating the cytoprotective effect of a variety of retinal cells against hyperglycemia." | 7.96 | Melatonin inhibits Müller cell activation and pro-inflammatory cytokine production via upregulating the MEG3/miR-204/Sirt1 axis in experimental diabetic retinopathy. ( Chen, L; Liu, W; Liu, X; Shi, Q; Song, E; Sun, Y; Tu, Y; Wang, K; Wang, X; Wang, Z; Zhao, Q; Zhu, M, 2020) |
| "The present study analyzed whether melatonin could mediate the expression of VEGF, IL-6 and TNF-α, as well as the apoptotic index in rats with diabetic retinopathy." | 7.96 | Melatonin regulates the expression of inflammatory cytokines, VEGF and apoptosis in diabetic retinopathy in rats. ( Almeida, LL; Bezerra de Sá, F; Cavalcanti Lapa Neto, CJ; Coelho Teixeira, ÁA; Ferreira de Melo, IM; Lima da Silva Souza, EH; Martins Ferreira, CG; Paz de Castro, MV; Teixeira, VW, 2020) |
| "To assess the diurnal melatonin, cortisol, and activity/rest levels, as well as sleep quality, in patients with and without nonproliferative diabetic retinopathy (DR)." | 7.91 | Assessment of diurnal melatonin, cortisol, activity, and sleep-wake cycle in patients with and without diabetic retinopathy. ( Andersen, HU; Ba-Ali, S; Brøndsted, AE; Jennum, PJ; Lund-Andersen, H; Sander, B, 2019) |
| "Melatonin also acts as a cell survival agent by modulating autophagy in various cell types and under different conditions through amelioration of oxidative stress, ER stress and inflammation." | 6.58 | Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. ( Dehdashtian, E; Ghaznavi, H; Hosseinzadeh, A; Mehrzadi, S; Naseripour, M; Reiter, RJ; Safa, M; Yousefi, B, 2018) |
| " In our study, we evaluate the effect of melatonin on the diabetic retinal alterations in male albino rats to the effect of melatonin combined with stem cells." | 5.91 | A comparative study between the possible protective role of melatonin versus its combination with adipose derived-mesenchymal stem cells on experimentally induced diabetic retinopathy in adult male albino rats (Histological and immunohistochemical study). ( Elsammak, GA; Elsayed, TG; Mostafa, SA; Reda, S, 2023) |
| "Melatonin (MEL) is a pleiotropic neurohormone of increasing interest as a neuroprotective agent in ocular diseases." | 5.72 | Melatonin loaded hybrid nanomedicine: DoE approach, optimization and in vitro study on diabetic retinopathy model. ( Bonaccorso, A; Bucolo, C; Caggia, C; Carbone, C; Daniela Anfuso, C; Giurdanella, G; Lupo, G; Musumeci, T; Pignatello, R; Randazzo, C; Rizzo, M; Romano, GL; Romeo, A; Ruozi, B; Russo, N; Thomas Duskey, J; Tosi, G, 2022) |
| "Melatonin has attracted extensive attention due to its potent antioxidant and anti-inflammatory effects." | 5.62 | Melatonin attenuates oxidative stress and inflammation of Müller cells in diabetic retinopathy via activating the Sirt1 pathway. ( Ji, N; Liu, X; Song, E; Sun, H; Tu, Y; Wang, K; Wang, Z; Zhang, Y; Zhu, L; Zhu, M; Zhu, Q, 2021) |
| "Melatonin is an endogenous neurohormone possessing various biological properties, including the regulation of oxidative stress, inflammation, autophagy, and angiogenesis functions." | 5.62 | Melatonin exerts protective effects on diabetic retinopathy via inhibition of Wnt/β-catenin pathway as revealed by quantitative proteomics. ( Gu, Y; Li, X; Lu, P; Tao, L; Wang, H; Yan, M, 2021) |
| "Melatonin acts as an antioxidant and regulator of mitochondrial bioenergetics and has a protective effect against ocular diseases." | 5.62 | Melatonin prevents blood-retinal barrier breakdown and mitochondrial dysfunction in high glucose and hypoxia-induced in vitro diabetic macular edema model. ( Chasan, T; Doğanlar, O; Doğanlar, ZB; Güçlü, H; Kurtdere, K; Turgut, E, 2021) |
| "Melatonin is a pineal hormone that regulates circadian and seasonal rhythms and most likely is involved in regulating glucose metabolism." | 5.48 | Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes. ( Basic, J; Cvetkovic, T; Despotovic, M; Djordjevic, B; Kocic, G; Pavlovic, D; Sokolovic, D; Stoimenov, TJ; Velickov, A; Veljkovic, A; Zivanovic, S, 2018) |
| "Melatonin is an endogenous hormone that exhibits a variety of biological effects including antioxidant and anti-inflammatory functions." | 5.43 | Protective Effects of Melatonin on Retinal Inflammation and Oxidative Stress in Experimental Diabetic Retinopathy. ( Cai, J; Chang, Q; Fan, J; Jiang, T; Xu, G; Zhang, X, 2016) |
| "Melatonin is a powerful antioxidant." | 5.40 | Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes. ( Cao, H; Chen, W; Lu, QY; Wang, N; Xu, X; Zhao, SZ; Zheng, Z, 2014) |
| "Recent evidence suggests that diabetic retinopathy (DR) is associated with abnormal melatonin regulation, possibly related to dysfunction of the melanopsin-expressing intrinsically photosensitive retinal ganglion cells." | 4.02 | Sleep variability, 6-sulfatoxymelatonin, and diabetic retinopathy. ( Chailurkit, LO; Chirakalwasan, N; Gerber, BS; Nimitphong, H; Pinyopodjanard, S; Reutrakul, S; Saetung, S; Sirisreetreerux, S; Sujirakul, T, 2021) |
| " Melatonin is a strong anti-inflammatory hormone, mediating the cytoprotective effect of a variety of retinal cells against hyperglycemia." | 3.96 | Melatonin inhibits Müller cell activation and pro-inflammatory cytokine production via upregulating the MEG3/miR-204/Sirt1 axis in experimental diabetic retinopathy. ( Chen, L; Liu, W; Liu, X; Shi, Q; Song, E; Sun, Y; Tu, Y; Wang, K; Wang, X; Wang, Z; Zhao, Q; Zhu, M, 2020) |
| "The present study analyzed whether melatonin could mediate the expression of VEGF, IL-6 and TNF-α, as well as the apoptotic index in rats with diabetic retinopathy." | 3.96 | Melatonin regulates the expression of inflammatory cytokines, VEGF and apoptosis in diabetic retinopathy in rats. ( Almeida, LL; Bezerra de Sá, F; Cavalcanti Lapa Neto, CJ; Coelho Teixeira, ÁA; Ferreira de Melo, IM; Lima da Silva Souza, EH; Martins Ferreira, CG; Paz de Castro, MV; Teixeira, VW, 2020) |
| "To assess the diurnal melatonin, cortisol, and activity/rest levels, as well as sleep quality, in patients with and without nonproliferative diabetic retinopathy (DR)." | 3.91 | Assessment of diurnal melatonin, cortisol, activity, and sleep-wake cycle in patients with and without diabetic retinopathy. ( Andersen, HU; Ba-Ali, S; Brøndsted, AE; Jennum, PJ; Lund-Andersen, H; Sander, B, 2019) |
| "Hyperglycemia increased retinal oxidation as measured through levels of nitrotyrosine and malondialdehyde." | 3.80 | Melatonin prevents retinal oxidative stress and vascular changes in diabetic rats. ( Bakariş, S; Durdu, H; Ergün, Y; Ganiyusufoğlu, E; Kılınç, M; Ozdemir, G, 2014) |
| "Melatonin is a hormone secreted by the pineal gland under the control of the circadian rhythm, and is released in the dark and suppressed during the day." | 2.61 | A new prospective on the role of melatonin in diabetes and its complications. ( Chye, SM; Koh, RY; Mok, JX; Ng, KY; Ooi, JH, 2019) |
| "Melatonin also acts as a cell survival agent by modulating autophagy in various cell types and under different conditions through amelioration of oxidative stress, ER stress and inflammation." | 2.58 | Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. ( Dehdashtian, E; Ghaznavi, H; Hosseinzadeh, A; Mehrzadi, S; Naseripour, M; Reiter, RJ; Safa, M; Yousefi, B, 2018) |
| " In our study, we evaluate the effect of melatonin on the diabetic retinal alterations in male albino rats to the effect of melatonin combined with stem cells." | 1.91 | A comparative study between the possible protective role of melatonin versus its combination with adipose derived-mesenchymal stem cells on experimentally induced diabetic retinopathy in adult male albino rats (Histological and immunohistochemical study). ( Elsammak, GA; Elsayed, TG; Mostafa, SA; Reda, S, 2023) |
| "Melatonin (MEL) is a pleiotropic neurohormone of increasing interest as a neuroprotective agent in ocular diseases." | 1.72 | Melatonin loaded hybrid nanomedicine: DoE approach, optimization and in vitro study on diabetic retinopathy model. ( Bonaccorso, A; Bucolo, C; Caggia, C; Carbone, C; Daniela Anfuso, C; Giurdanella, G; Lupo, G; Musumeci, T; Pignatello, R; Randazzo, C; Rizzo, M; Romano, GL; Romeo, A; Ruozi, B; Russo, N; Thomas Duskey, J; Tosi, G, 2022) |
| "Melatonin is an endogenous neurohormone possessing various biological properties, including the regulation of oxidative stress, inflammation, autophagy, and angiogenesis functions." | 1.62 | Melatonin exerts protective effects on diabetic retinopathy via inhibition of Wnt/β-catenin pathway as revealed by quantitative proteomics. ( Gu, Y; Li, X; Lu, P; Tao, L; Wang, H; Yan, M, 2021) |
| "People with type 2 diabetes (T2D) suffer from sleep disorders, with the mechanism not clearly understood." | 1.62 | Supplemental light exposure improves sleep architecture in people with type 2 diabetes. ( Adhikari, P; Feigl, B; Pradhan, A; Zele, AJ, 2021) |
| "Melatonin acts as an antioxidant and regulator of mitochondrial bioenergetics and has a protective effect against ocular diseases." | 1.62 | Melatonin prevents blood-retinal barrier breakdown and mitochondrial dysfunction in high glucose and hypoxia-induced in vitro diabetic macular edema model. ( Chasan, T; Doğanlar, O; Doğanlar, ZB; Güçlü, H; Kurtdere, K; Turgut, E, 2021) |
| "Melatonin is a pineal hormone that regulates circadian and seasonal rhythms and most likely is involved in regulating glucose metabolism." | 1.48 | Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes. ( Basic, J; Cvetkovic, T; Despotovic, M; Djordjevic, B; Kocic, G; Pavlovic, D; Sokolovic, D; Stoimenov, TJ; Velickov, A; Veljkovic, A; Zivanovic, S, 2018) |
| "As diabetic retinopathy may affect melatonin secretion, we also explore the relationship between retinopathy, melatonin and glycemic control." | 1.46 | Associations between nocturnal urinary 6-sulfatoxymelatonin, obstructive sleep apnea severity and glycemic control in type 2 diabetes. ( Chailurkit, LO; Chirakalwasan, N; Nimitphong, H; Ongphiphadhanakul, B; Reutrakul, S; Saetung, S; Siwasaranond, N; Srijaruskul, K; Thakkinstian, A, 2017) |
| "Melatonin is an endogenous hormone that exhibits a variety of biological effects including antioxidant and anti-inflammatory functions." | 1.43 | Protective Effects of Melatonin on Retinal Inflammation and Oxidative Stress in Experimental Diabetic Retinopathy. ( Cai, J; Chang, Q; Fan, J; Jiang, T; Xu, G; Zhang, X, 2016) |
| "Melatonin is a powerful antioxidant." | 1.40 | Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes. ( Cao, H; Chen, W; Lu, QY; Wang, N; Xu, X; Zhao, SZ; Zheng, Z, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 13 (52.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oliveira-Abreu, K | 1 |
| Cipolla-Neto, J | 2 |
| Leal-Cardoso, JH | 1 |
| Tang, L | 2 |
| Zhang, C | 2 |
| Lu, L | 2 |
| Tian, H | 2 |
| Liu, K | 2 |
| Luo, D | 2 |
| Qiu, Q | 2 |
| Xu, GT | 2 |
| Zhang, J | 2 |
| Romeo, A | 1 |
| Bonaccorso, A | 1 |
| Carbone, C | 1 |
| Lupo, G | 1 |
| Daniela Anfuso, C | 1 |
| Giurdanella, G | 1 |
| Caggia, C | 1 |
| Randazzo, C | 1 |
| Russo, N | 1 |
| Romano, GL | 1 |
| Bucolo, C | 1 |
| Rizzo, M | 1 |
| Tosi, G | 1 |
| Thomas Duskey, J | 1 |
| Ruozi, B | 1 |
| Pignatello, R | 1 |
| Musumeci, T | 1 |
| Reda, S | 1 |
| Elsammak, GA | 1 |
| Elsayed, TG | 1 |
| Mostafa, SA | 1 |
| Mok, JX | 1 |
| Ooi, JH | 1 |
| Ng, KY | 1 |
| Koh, RY | 1 |
| Chye, SM | 1 |
| Reutrakul, S | 3 |
| Crowley, SJ | 1 |
| Park, JC | 1 |
| Chau, FY | 1 |
| Priyadarshini, M | 1 |
| Hanlon, EC | 1 |
| Danielson, KK | 1 |
| Gerber, BS | 2 |
| Baynard, T | 1 |
| Yeh, JJ | 1 |
| McAnany, JJ | 1 |
| Tu, Y | 2 |
| Zhu, M | 2 |
| Wang, Z | 2 |
| Wang, K | 2 |
| Chen, L | 1 |
| Liu, W | 1 |
| Shi, Q | 1 |
| Zhao, Q | 1 |
| Sun, Y | 1 |
| Wang, X | 1 |
| Song, E | 2 |
| Liu, X | 2 |
| Ferreira de Melo, IM | 1 |
| Martins Ferreira, CG | 1 |
| Lima da Silva Souza, EH | 1 |
| Almeida, LL | 1 |
| Bezerra de Sá, F | 1 |
| Cavalcanti Lapa Neto, CJ | 1 |
| Paz de Castro, MV | 1 |
| Teixeira, VW | 1 |
| Coelho Teixeira, ÁA | 1 |
| Sirisreetreerux, S | 1 |
| Sujirakul, T | 1 |
| Nimitphong, H | 2 |
| Pinyopodjanard, S | 1 |
| Saetung, S | 2 |
| Chailurkit, LO | 2 |
| Chirakalwasan, N | 2 |
| Yang, Q | 1 |
| Xie, H | 1 |
| Liu, D | 1 |
| Xu, JY | 1 |
| Li, W | 1 |
| Xu, G | 2 |
| Ji, N | 1 |
| Zhu, L | 1 |
| Sun, H | 1 |
| Zhang, Y | 1 |
| Zhu, Q | 1 |
| Yan, M | 1 |
| Wang, H | 1 |
| Gu, Y | 1 |
| Li, X | 1 |
| Tao, L | 1 |
| Lu, P | 1 |
| Adhikari, P | 1 |
| Pradhan, A | 1 |
| Zele, AJ | 1 |
| Feigl, B | 1 |
| Doğanlar, ZB | 1 |
| Doğanlar, O | 1 |
| Kurtdere, K | 1 |
| Güçlü, H | 1 |
| Chasan, T | 1 |
| Turgut, E | 1 |
| Dehdashtian, E | 1 |
| Mehrzadi, S | 2 |
| Yousefi, B | 1 |
| Hosseinzadeh, A | 1 |
| Reiter, RJ | 1 |
| Safa, M | 1 |
| Ghaznavi, H | 2 |
| Naseripour, M | 1 |
| Motevalian, M | 1 |
| Rezaei Kanavi, M | 1 |
| Fatemi, I | 1 |
| Shahriari, M | 1 |
| Djordjevic, B | 1 |
| Cvetkovic, T | 1 |
| Stoimenov, TJ | 1 |
| Despotovic, M | 1 |
| Zivanovic, S | 1 |
| Basic, J | 1 |
| Veljkovic, A | 1 |
| Velickov, A | 1 |
| Kocic, G | 1 |
| Pavlovic, D | 1 |
| Sokolovic, D | 1 |
| Ba-Ali, S | 1 |
| Brøndsted, AE | 1 |
| Andersen, HU | 1 |
| Sander, B | 1 |
| Jennum, PJ | 1 |
| Lund-Andersen, H | 1 |
| Chang, JY | 1 |
| Yu, F | 1 |
| Shi, L | 1 |
| Ko, ML | 1 |
| Ko, GY | 1 |
| Ozdemir, G | 1 |
| Ergün, Y | 1 |
| Bakariş, S | 1 |
| Kılınç, M | 1 |
| Durdu, H | 1 |
| Ganiyusufoğlu, E | 1 |
| Chen, W | 1 |
| Cao, H | 1 |
| Lu, QY | 1 |
| Wang, N | 1 |
| Zhao, SZ | 1 |
| Xu, X | 1 |
| Zheng, Z | 1 |
| Jiang, T | 1 |
| Chang, Q | 1 |
| Cai, J | 1 |
| Fan, J | 1 |
| Zhang, X | 1 |
| Siwasaranond, N | 1 |
| Srijaruskul, K | 1 |
| Ongphiphadhanakul, B | 1 |
| Thakkinstian, A | 1 |
| do Carmo Buonfiglio, D | 1 |
| Peliciari-Garcia, RA | 1 |
| do Amaral, FG | 1 |
| Peres, R | 1 |
| Nogueira, TC | 1 |
| Afeche, SC | 1 |
| Salido, EM | 1 |
| Bordone, M | 1 |
| De Laurentiis, A | 1 |
| Chianelli, M | 1 |
| Keller Sarmiento, MI | 1 |
| Dorfman, D | 1 |
| Rosenstein, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Controlled Trial of Bright Light Therapy on All-Cause Excessive Daytime Sleepiness in Prader-Willi Syndrome[NCT05939453] | 30 participants (Anticipated) | Interventional | 2023-10-01 | Recruiting | |||
| Effects of Melatonin on Progression of Coronary Artery Calcification[NCT03966235] | Phase 4 | 74 participants (Anticipated) | Interventional | 2019-06-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for melatonin and Diabetic Retinopathy
| Article | Year |
|---|---|
Effects of Melatonin on Diabetic Neuropathy and Retinopathy.
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Diabetic Retinopathy; Hum | 2021 |
A new prospective on the role of melatonin in diabetes and its complications.
Topics: Animals; Antioxidants; Apoptosis; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus; Diabe | 2019 |
Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress.
Topics: Apoptosis; Autophagy; Cell Survival; Diabetes Complications; Diabetic Retinopathy; Humans; Inflammat | 2018 |
22 other studies available for melatonin and Diabetic Retinopathy
| Article | Year |
|---|---|
Melatonin Maintains Inner Blood-Retinal Barrier by Regulating Microglia
Topics: Animals; Blood-Retinal Barrier; Diabetes Mellitus; Diabetic Retinopathy; Endothelial Cells; Melatoni | 2022 |
Melatonin loaded hybrid nanomedicine: DoE approach, optimization and in vitro study on diabetic retinopathy model.
Topics: Antioxidants; Delayed-Action Preparations; Diabetes Mellitus; Diabetic Retinopathy; Drug Carriers; H | 2022 |
A comparative study between the possible protective role of melatonin versus its combination with adipose derived-mesenchymal stem cells on experimentally induced diabetic retinopathy in adult male albino rats (Histological and immunohistochemical study).
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Melatonin; Mesenchymal Stem Ce | 2023 |
Relationship between Intrinsically Photosensitive Ganglion Cell Function and Circadian Regulation in Diabetic Retinopathy.
Topics: Adie Syndrome; Aged; Cells, Cultured; Circadian Clocks; Cross-Sectional Studies; Diabetes Mellitus, | 2020 |
Melatonin inhibits Müller cell activation and pro-inflammatory cytokine production via upregulating the MEG3/miR-204/Sirt1 axis in experimental diabetic retinopathy.
Topics: Animals; Apoptosis; Cytokines; Diabetes Mellitus; Diabetic Retinopathy; Ependymoglial Cells; Hypergl | 2020 |
Melatonin regulates the expression of inflammatory cytokines, VEGF and apoptosis in diabetic retinopathy in rats.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Interleukin-6; Melatonin; | 2020 |
Sleep variability, 6-sulfatoxymelatonin, and diabetic retinopathy.
Topics: Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Humans; Male; | 2021 |
Melatonin maintains inner blood-retinal barrier via inhibition of p38/TXNIP/NF-κB pathway in diabetic retinopathy.
Topics: Animals; Antioxidants; Blood-Retinal Barrier; Capillary Permeability; Diabetic Retinopathy; Endothel | 2021 |
Melatonin attenuates oxidative stress and inflammation of Müller cells in diabetic retinopathy via activating the Sirt1 pathway.
Topics: Acetylation; Animals; Animals, Newborn; Anti-Inflammatory Agents; Antioxidants; Diabetic Retinopathy | 2021 |
Melatonin exerts protective effects on diabetic retinopathy via inhibition of Wnt/β-catenin pathway as revealed by quantitative proteomics.
Topics: Animals; Antioxidants; Blood-Retinal Barrier; Blotting, Western; Cell Movement; Cell Proliferation; | 2021 |
Supplemental light exposure improves sleep architecture in people with type 2 diabetes.
Topics: Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Melatonin; Sleep | 2021 |
Melatonin prevents blood-retinal barrier breakdown and mitochondrial dysfunction in high glucose and hypoxia-induced in vitro diabetic macular edema model.
Topics: Apoptosis; Aryl Hydrocarbon Receptor Nuclear Translocator; Blood-Retinal Barrier; Cell Hypoxia; Cell | 2021 |
Protective effect of melatonin in the diabetic rat retina.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; M | 2018 |
Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Humans; | 2018 |
Assessment of diurnal melatonin, cortisol, activity, and sleep-wake cycle in patients with and without diabetic retinopathy.
Topics: Actigraphy; Circadian Rhythm; Diabetes Mellitus; Diabetic Retinopathy; Female; Humans; Hydrocortison | 2019 |
Melatonin Affects Mitochondrial Fission/Fusion Dynamics in the Diabetic Retina.
Topics: Adenosine Triphosphate; Angiography; Animals; Calcium; Diabetes Mellitus, Experimental; Diabetic Ret | 2019 |
Melatonin prevents retinal oxidative stress and vascular changes in diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Retinopa | 2014 |
Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Hu | 2014 |
Protective Effects of Melatonin on Retinal Inflammation and Oxidative Stress in Experimental Diabetic Retinopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Melatonin; Oxidative Stress; R | 2016 |
Associations between nocturnal urinary 6-sulfatoxymelatonin, obstructive sleep apnea severity and glycemic control in type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Circadian Rhythm; Creatinine; Diabetes Mellitus, Type 2; Diabetic Retino | 2017 |
Early-stage retinal melatonin synthesis impairment in streptozotocin-induced diabetic wistar rats.
Topics: Animals; ARNTL Transcription Factors; Arylalkylamine N-Acetyltransferase; Cell Survival; Chromatogra | 2011 |
Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats.
Topics: Animals; Catalase; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Electroretinography; Glucose; Im | 2013 |